These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Past, imminent and future human medical countermeasures for anthrax. Baillie LW J Appl Microbiol; 2006 Sep; 101(3):594-606. PubMed ID: 16907809 [TBL] [Abstract][Full Text] [Related]
24. Comparative secretome analyses of three Bacillus anthracis strains with variant plasmid contents. Lamonica JM; Wagner M; Eschenbrenner M; Williams LE; Miller TL; Patra G; DelVecchio VG Infect Immun; 2005 Jun; 73(6):3646-58. PubMed ID: 15908394 [TBL] [Abstract][Full Text] [Related]
25. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Sloat BR; Cui Z Vaccine; 2006 Sep; 24(40-41):6405-13. PubMed ID: 16828937 [TBL] [Abstract][Full Text] [Related]
26. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760 [TBL] [Abstract][Full Text] [Related]
27. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Vipond C; Suker J; Jones C; Tang C; Feavers IM; Wheeler JX Proteomics; 2006 Jun; 6(11):3400-13. PubMed ID: 16645985 [TBL] [Abstract][Full Text] [Related]
28. Toxoplasma gondii: proteomic analysis of antigenicity of soluble tachyzoite antigen. Ma GY; Zhang JZ; Yin GR; Zhang JH; Meng XL; Zhao F Exp Parasitol; 2009 May; 122(1):41-6. PubMed ID: 19545523 [TBL] [Abstract][Full Text] [Related]
29. The 2beta2-2beta3 loop of anthrax protective antigen contains a dominant neutralizing epitope. Zhang J; Xu J; Li G; Dong D; Song X; Guo Q; Zhao J; Fu L; Chen W Biochem Biophys Res Commun; 2006 Mar; 341(4):1164-71. PubMed ID: 16460675 [TBL] [Abstract][Full Text] [Related]
30. Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization. Herrmann JE; Wang S; Zhang C; Panchal RG; Bavari S; Lyons CR; Lovchik JA; Golding B; Shiloach J; Lu S Vaccine; 2006 Jul; 24(31-32):5872-80. PubMed ID: 16790303 [TBL] [Abstract][Full Text] [Related]
31. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Lee JS; Groebner JL; Hadjipanayis AG; Negley DL; Schmaljohn AL; Welkos SL; Smith LA; Smith JF Vaccine; 2006 Nov; 24(47-48):6886-92. PubMed ID: 16828936 [TBL] [Abstract][Full Text] [Related]
32. Catalytically inactive anthrax toxin(s) are potential prophylactic agents. Gupta M; Alam S; Bhatnagar R Vaccine; 2007 Dec; 25(50):8410-9. PubMed ID: 17980467 [TBL] [Abstract][Full Text] [Related]
33. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Cote CK; Rossi CA; Kang AS; Morrow PR; Lee JS; Welkos SL Microb Pathog; 2005; 38(5-6):209-25. PubMed ID: 15925272 [TBL] [Abstract][Full Text] [Related]
34. Production and purification of Bacillus anthracis protective antigen from Escherichia coli. Laird MW; Zukauskas D; Johnson K; Sampey GC; Olsen H; Garcia A; Karwoski JD; Cooksey BA; Choi GH; Askins J; Tsai A; Pierre J; Gwinn W Protein Expr Purif; 2004 Nov; 38(1):145-52. PubMed ID: 15477093 [TBL] [Abstract][Full Text] [Related]
35. [Toxin-neutralizing monoclonal antibodies to the different domains of anthrax protective antigen]. Xu JJ; Zhang J; Liu SL; Lv TJ; Chen W; Li GL; Ge M; Guo Q Wei Sheng Wu Xue Bao; 2005 Dec; 45(6):947-51. PubMed ID: 16496709 [TBL] [Abstract][Full Text] [Related]
36. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis. Tournier JN; Ulrich RG; Quesnel-Hellmann A; Mohamadzadeh M; Stiles BG Expert Rev Anti Infect Ther; 2009 Mar; 7(2):219-36. PubMed ID: 19254170 [TBL] [Abstract][Full Text] [Related]
37. DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components. Hahn UK; Boehm R; Beyer W Vaccine; 2006 May; 24(21):4569-71. PubMed ID: 16157424 [TBL] [Abstract][Full Text] [Related]
38. Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. Uli L; Castellanos-Serra L; Betancourt L; Domínguez F; Barberá R; Sotolongo F; Guillén G; Pajón Feyt R Proteomics; 2006 Jun; 6(11):3389-99. PubMed ID: 16673438 [TBL] [Abstract][Full Text] [Related]
39. Identification of antigenic proteins from Echinostoma caproni (Trematoda) recognized by mouse immunoglobulins M, A and G using an immunoproteomic approach. Sotillo J; Valero L; Sánchez Del Pino MM; Fried B; Esteban JG; Marcilla A; Toledo R Parasite Immunol; 2008 May; 30(5):271-9. PubMed ID: 18221450 [TBL] [Abstract][Full Text] [Related]
40. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis. Kaur M; Chug H; Singh H; Chandra S; Mishra M; Sharma M; Bhatnagar R Mol Immunol; 2009 Jun; 46(10):2107-15. PubMed ID: 19356802 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]